Manufacturer for Indacaterol Maleate - Eptifibatide for Treatment of Acute Coronary Syndrome 188627-80-7 – Gentolex
Manufacturer for Indacaterol Maleate - Eptifibatide for Treatment of Acute Coronary Syndrome 188627-80-7 – Gentolex Detail:
Product Detail
| Name | Eptifibatide |
| CAS number | 188627-80-7 |
| Molecular formula | C35H49N11O9S2 |
| Molecular weight | 831.96 |
| EINECS Number | 641-366-7 |
| Density | 1.60±0.1 g/cm3(Predicted) |
| Storage conditions | Sealed in dry, store in freezer, under -15°C |
Synonyms
Eptifibatideacetatesalt;Eptifibatide,MPA-HAR-Gly-Asp-Trp-Pro-Cys-NH2,MPAHARGDWPC-NH2,>99%;MAP-LYS-GLY-ASP-TRP-PRO-CYS-NH2;INTEGRELIN;Eptifibatide;N6-(Aminoiminomethyl)-N2-(3-mercapto-1-oxopropyl-L-lysylglycyl-L-a-aspartyl-L-tryptophyl-L-prolyl-L-cysteinamide;MPA-HAR-GLY-ASP-TRP-PRO-CYS-NH2(DISULFIDEBRIDGE,MPA1-CYS6).
Platelet Glycoprotein Antagonist
Etifibatide (integrilin) is a novel polypeptide platelet glycoprotein IIb/IIIa receptor antagonist, which inhibits platelet aggregation and thrombosis by inhibiting the last common pathway of platelet aggregation. Compared with the monoclonal antibody abciximab, eptifibatide has a stronger, more directional and specific binding to GPIIb/IIIa due to the existence of a single conservative amino acid substitution—lysine to replace arginine. Therefore, it should have a good therapeutic effect in the interventional treatment of acute coronary syndrome. Platelet glycoprotein IIb/IIIa receptor antagonist drugs have been developed a lot, and currently there are 3 kinds of preparations that can be used in clinical internationally, abciximab, eptifibatide and tirofiban. ). There is little experience in the use of platelet glycoprotein GPIIb/IIIa receptor antagonists in China, and the available drugs are also very limited. Only one drug, tirofiban hydrochloride, is on the market. Therefore, a new platelet glycoprotein IIb was developed. /IIIa receptor antagonists are imperative. Domestic eptifibatide is an imitation product produced by Chengdu Sino Biological Products Co., Ltd.
Classification
Classification of Antiplatelet Aggregation Drugs
Antiplatelet aggregation drugs can be roughly divided into three categories: 1. Cyclooxygenase-1 (COX-1) inhibitors, such as aspirin. 2. Inhibit platelet aggregation induced by adenosine diphosphate (ADP), such as clopidogrel, prasugrel, cangrelor, ticagrelor, etc. 3. Platelet glycoprotein Ⅱb/Ⅲa receptor antagonists, such as abciximab, eptifibatide, tirofiban, etc. In addition, there are prostaglandin EP3 receptor inhibitors, newly synthesized chemical components and effective extracts from traditional Chinese medicine.
Product detail pictures:
Related Product Guide:
Persisting in "High top quality, Prompt Delivery, Aggressive Price", now we have established long-term cooperation with customers from the two overseas and domestically and get new and aged clients' large comments for Manufacturer for Indacaterol Maleate - Eptifibatide for Treatment of Acute Coronary Syndrome 188627-80-7 – Gentolex , The product will supply to all over the world, such as: Slovak Republic, Mauritania, Las Vegas, They're durable modeling and promoting well all over the world. Under no circumstances disappearing key functions in a brief time, it's a should for you personally of fantastic quality. Guided by the principle of Prudence, Efficiency, Union and Innovation. the business make an awesome efforts to expand its international trade, raise its enterprise. rofit and improve its export scale. We are confident that we'll have a vibrant prospect and to be distributed all over the world in the years to come.
By Alexia from Chile - 2018.06.12 16:22
The company's products very well, we have purchased and cooperated many times, fair price and assured quality, in short, this is a trustworthy company!
By Phyllis from Malawi - 2017.11.01 17:04
